This template was built with Webflow's free Prospero UI Kit. Learn more
When a child is diagnosed with an SCN2A loss of function (LOF) disorder, parents are often handed a term they have never encountered before. The diagnosis can feel both clarifying and overwhelming at the same time — clarifying because there is finally a name for what your family has been living through, and overwhelming because the science can seem impenetrable. This guide is written to change that.
SCN2A-related disorders affect the brain's electrical signaling system. Understanding whether your child has a loss of function or gain of function variant is one of the most clinically informative pieces of information a family can have — because the two types of mutations affect the brain differently, present with different features, and call for different approaches in care and research. This distinction also explains what SCN2A is and why it matters so much to get it right.
The SCN2A gene carries the instructions for building a protein called Nav1.2 (sodium channel, voltage-gated, type 1.2). Nav1.2 is a type of ion channel — think of it as a tiny gateway embedded in the surface of brain cells (neurons). Its job is to control the flow of sodium into the neuron, which generates and transmits the electrical signals neurons use to communicate.
Nav1.2 is especially active during early brain development. It plays a central role in initiating and propagating action potentials — the electrical pulses that carry information through the nervous system. Because Nav1.2 is expressed at particularly high levels in the developing brain, mutations in SCN2A can have significant effects on how the brain forms and functions, particularly in early childhood. During development, Nav1.2 is later partially replaced by Nav1.6 in key neuronal regions, which contributes to age-dependent clinical features.
A loss of function (LOF) mutation in SCN2A reduces or eliminates the normal activity of the Nav1.2 channel. Instead of a fully operational gateway, the cell is working with a channel that is underactive — passing less sodium current than it should. This often reduces the intrinsic excitability of individual neurons, although in some contexts it can lead to altered network activity and even increased excitability at the circuit level.
Many LOF mutations in SCN2A occur as de novo variants — meaning they arise spontaneously and are not inherited from either parent. Many LOF variants produce what researchers call haploinsufficiency: only one of the two copies of the SCN2A gene is working properly, and the remaining functional copy is not enough to fully compensate. Research in mouse models has shown that Nav1.2 haploinsufficiency has been shown to alter neuronal excitability and disrupt activity in brain circuits involved in learning and memory, with effects that can vary by developmental stage.
This reduced channel activity stands in direct contrast to gain of function mutations, where the channel is overactive. That fundamental biological difference is why LOF and GOF disorders look different clinically — and why they require fundamentally different approaches in research and care.
Recent research suggests that SCN2A loss of function particularly affects dendritic signaling and synaptic integration, which may contribute to its strong association with autism and cognitive differences.
SCN2A variants exist on a functional spectrum. At one end, gain of function (GOF) variants cause the Nav1.2 channel to be overactive, flooding neurons with excess sodium current. This neuronal over-excitability is most commonly associated with early-onset epileptic encephalopathy, often within the first months of life.
At the other end, loss of function (LOF) variants reduce channel activity. Research in large clinical cohorts has shown that predicted severe or truncating LOF variants are associated with later-onset epilepsy, autism spectrum disorder (ASD), and intellectual disability — often with seizure onset occurring after the first year of life, or with no seizure history at all. Mixed function variants fall between these two poles, with some electrophysiological parameters showing GOF characteristics and others showing LOF characteristics.
This genotype-phenotype relationship — the connection between the type of variant and the clinical presentation — is one of the better-characterized genotype-phenotype relationships in rare neurodevelopmental disorders. It has direct implications for care, because treatment strategies that are appropriate for one mutation type may not be appropriate for another. Families navigating an LOF diagnosis should discuss this distinction in detail with their child’s neurologist and genetics team.
For many children with predicted severe or truncating SCN2A LOF variants, the primary diagnosis is autism spectrum disorder (ASD) and/or intellectual disability (ID) — sometimes without any seizure history. Research analyzing the relationship between variant function and clinical phenotype in SCN2A-related disorders has found that predicted severe or truncating LOF variants are associated with this ASD/ID group, which tends to have less severe seizure burden compared to early-onset epilepsy groups, though developmental impacts can still be significant.
Children with SCN2A LOF and ASD may show delays in language, social communication, and adaptive functioning. Each child's profile is different, and the degree of intellectual disability can range from mild to significant. Developmental supports, speech and language therapy, occupational therapy, and behavioral intervention are among the approaches that care teams may consider, tailored to each child's individual strengths and needs.
A subset of children with LOF variants do experience seizures — but these tend to present later than those seen in GOF disorders, often beginning after 12 months of age or later in childhood. The seizure types and their severity vary. In some children, seizure control is achievable; in others, seizures are more challenging to manage.
Understanding your child's specific variant — and having it characterized functionally — is an important step in working with a neurologist to build an appropriate care plan. You can explore active SCN2A research that is helping to build the evidence base for more precise, genotype-informed treatment approaches.
One of the most clinically critical distinctions between LOF and GOF disorders involves a class of medications known as sodium channel blockers (SCBs) — anti-seizure medications that work by reducing sodium channel activity. Examples include oxcarbazepine, carbamazepine, and phenytoin.
For children with GOF mutations, where the channel is already overactive, sodium channel blockers can be an appropriate treatment approach under the guidance of a specialist. For children with LOF mutations, however, the channel is already underactive. Sodium channel blockers are generally avoided in LOF variants, as they may worsen symptoms in some cases. Published research and clinical guidance consistently reflect this distinction.
This is why genetic testing and functional characterization of your child’s specific SCN2A variant is so important — not only for understanding the diagnosis, but for ensuring the care your child receives is matched to the biology of their mutation. If you have questions about your child’s medications and their SCN2A variant type, please consult a qualified neurologist or geneticist with experience in SCN2A-related disorders.
Because SCN2A LOF disorders result from insufficient Nav1.2 channel activity, the therapeutic goal is the reverse of GOF: researchers are working to increase SCN2A expression from the remaining functional gene copy, rather than suppress it.
One of the most promising approaches is CRISPR activation (CRISPRa) — a gene therapy strategy that uses a modified version of the CRISPR system not to cut DNA, but to boost the expression of a gene. A landmark 2025 study published in Nature (Tamura et al., UCSF) demonstrated that CRISPRa delivered via an adeno-associated virus (AAV) vector partially restored SCN2A expression and improved neurological features in mouse models of SCN2A haploinsufficiency — including when treatment was initiated during adolescent-equivalent developmental stages. The study also showed that CRISPRa-treated mice had restored protection against seizures induced by chemical agents, suggesting potential benefit for both the neurodevelopmental and epilepsy features of LOF disorders.
The CRISPRa findings are early-stage — they represent preclinical research in animal models and human stem cell-derived neurons, not yet a clinical therapy available to patients. But their significance lies in suggesting the possibility that the therapeutic window may be broader than previously assumed: rescuing SCN2A expression even after early development could have meaningful neurological benefit. This is a hopeful signal for families of older children who may have wondered whether it was too late for targeted treatment.
Research into other gene activation platforms, including AAV-based gene therapy approaches, is also ongoing. The SCN2A field is advancing quickly, with growing investment from both academic institutions and the biotech sector. Families can support this momentum — and stay informed — by joining the SCN2A patient registry, which helps researchers understand the full scope of the LOF patient population and accelerates the path to clinical trials.
Research into SCN2A loss of function disorders has advanced meaningfully in recent years — but there is still a long road ahead to bring targeted therapies from laboratory findings to the families who need them most. Every family that registers, every dollar donated, and every story shared contributes to that journey.
Every family navigating an SCN2A loss of function diagnosis deserves answers, community, and hope. The work to find them depends on your support. Please consider making a donation to help fund the research and resources that move us all forward.
This content is provided for educational and informational purposes only and does not constitute medical advice. The information on this page is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.
4. Tamura S, et al. CRISPR Activation for SCN2A-Related Neurodevelopmental Disorders. Nature, 2025.
Share
When a child is diagnosed with an SCN2A loss of function (LOF) disorder, parents are often handed a term they have never encountered before. The diagnosis can feel both clarifying and overwhelming at the same time — clarifying because there is finally a name for what your family has been living through, and overwhelming because the science can seem impenetrable. This guide is written to change that.
SCN2A-related disorders affect the brain's electrical signaling system. Understanding whether your child has a loss of function or gain of function variant is one of the most clinically informative pieces of information a family can have — because the two types of mutations affect the brain differently, present with different features, and call for different approaches in care and research. This distinction also explains what SCN2A is and why it matters so much to get it right.
The SCN2A gene carries the instructions for building a protein called Nav1.2 (sodium channel, voltage-gated, type 1.2). Nav1.2 is a type of ion channel — think of it as a tiny gateway embedded in the surface of brain cells (neurons). Its job is to control the flow of sodium into the neuron, which generates and transmits the electrical signals neurons use to communicate.
Nav1.2 is especially active during early brain development. It plays a central role in initiating and propagating action potentials — the electrical pulses that carry information through the nervous system. Because Nav1.2 is expressed at particularly high levels in the developing brain, mutations in SCN2A can have significant effects on how the brain forms and functions, particularly in early childhood. During development, Nav1.2 is later partially replaced by Nav1.6 in key neuronal regions, which contributes to age-dependent clinical features.
A loss of function (LOF) mutation in SCN2A reduces or eliminates the normal activity of the Nav1.2 channel. Instead of a fully operational gateway, the cell is working with a channel that is underactive — passing less sodium current than it should. This often reduces the intrinsic excitability of individual neurons, although in some contexts it can lead to altered network activity and even increased excitability at the circuit level.
Many LOF mutations in SCN2A occur as de novo variants — meaning they arise spontaneously and are not inherited from either parent. Many LOF variants produce what researchers call haploinsufficiency: only one of the two copies of the SCN2A gene is working properly, and the remaining functional copy is not enough to fully compensate. Research in mouse models has shown that Nav1.2 haploinsufficiency has been shown to alter neuronal excitability and disrupt activity in brain circuits involved in learning and memory, with effects that can vary by developmental stage.
This reduced channel activity stands in direct contrast to gain of function mutations, where the channel is overactive. That fundamental biological difference is why LOF and GOF disorders look different clinically — and why they require fundamentally different approaches in research and care.
Recent research suggests that SCN2A loss of function particularly affects dendritic signaling and synaptic integration, which may contribute to its strong association with autism and cognitive differences.
SCN2A variants exist on a functional spectrum. At one end, gain of function (GOF) variants cause the Nav1.2 channel to be overactive, flooding neurons with excess sodium current. This neuronal over-excitability is most commonly associated with early-onset epileptic encephalopathy, often within the first months of life.
At the other end, loss of function (LOF) variants reduce channel activity. Research in large clinical cohorts has shown that predicted severe or truncating LOF variants are associated with later-onset epilepsy, autism spectrum disorder (ASD), and intellectual disability — often with seizure onset occurring after the first year of life, or with no seizure history at all. Mixed function variants fall between these two poles, with some electrophysiological parameters showing GOF characteristics and others showing LOF characteristics.
This genotype-phenotype relationship — the connection between the type of variant and the clinical presentation — is one of the better-characterized genotype-phenotype relationships in rare neurodevelopmental disorders. It has direct implications for care, because treatment strategies that are appropriate for one mutation type may not be appropriate for another. Families navigating an LOF diagnosis should discuss this distinction in detail with their child’s neurologist and genetics team.
For many children with predicted severe or truncating SCN2A LOF variants, the primary diagnosis is autism spectrum disorder (ASD) and/or intellectual disability (ID) — sometimes without any seizure history. Research analyzing the relationship between variant function and clinical phenotype in SCN2A-related disorders has found that predicted severe or truncating LOF variants are associated with this ASD/ID group, which tends to have less severe seizure burden compared to early-onset epilepsy groups, though developmental impacts can still be significant.
Children with SCN2A LOF and ASD may show delays in language, social communication, and adaptive functioning. Each child's profile is different, and the degree of intellectual disability can range from mild to significant. Developmental supports, speech and language therapy, occupational therapy, and behavioral intervention are among the approaches that care teams may consider, tailored to each child's individual strengths and needs.
A subset of children with LOF variants do experience seizures — but these tend to present later than those seen in GOF disorders, often beginning after 12 months of age or later in childhood. The seizure types and their severity vary. In some children, seizure control is achievable; in others, seizures are more challenging to manage.
Understanding your child's specific variant — and having it characterized functionally — is an important step in working with a neurologist to build an appropriate care plan. You can explore active SCN2A research that is helping to build the evidence base for more precise, genotype-informed treatment approaches.
One of the most clinically critical distinctions between LOF and GOF disorders involves a class of medications known as sodium channel blockers (SCBs) — anti-seizure medications that work by reducing sodium channel activity. Examples include oxcarbazepine, carbamazepine, and phenytoin.
For children with GOF mutations, where the channel is already overactive, sodium channel blockers can be an appropriate treatment approach under the guidance of a specialist. For children with LOF mutations, however, the channel is already underactive. Sodium channel blockers are generally avoided in LOF variants, as they may worsen symptoms in some cases. Published research and clinical guidance consistently reflect this distinction.
This is why genetic testing and functional characterization of your child’s specific SCN2A variant is so important — not only for understanding the diagnosis, but for ensuring the care your child receives is matched to the biology of their mutation. If you have questions about your child’s medications and their SCN2A variant type, please consult a qualified neurologist or geneticist with experience in SCN2A-related disorders.
Because SCN2A LOF disorders result from insufficient Nav1.2 channel activity, the therapeutic goal is the reverse of GOF: researchers are working to increase SCN2A expression from the remaining functional gene copy, rather than suppress it.
One of the most promising approaches is CRISPR activation (CRISPRa) — a gene therapy strategy that uses a modified version of the CRISPR system not to cut DNA, but to boost the expression of a gene. A landmark 2025 study published in Nature (Tamura et al., UCSF) demonstrated that CRISPRa delivered via an adeno-associated virus (AAV) vector partially restored SCN2A expression and improved neurological features in mouse models of SCN2A haploinsufficiency — including when treatment was initiated during adolescent-equivalent developmental stages. The study also showed that CRISPRa-treated mice had restored protection against seizures induced by chemical agents, suggesting potential benefit for both the neurodevelopmental and epilepsy features of LOF disorders.
The CRISPRa findings are early-stage — they represent preclinical research in animal models and human stem cell-derived neurons, not yet a clinical therapy available to patients. But their significance lies in suggesting the possibility that the therapeutic window may be broader than previously assumed: rescuing SCN2A expression even after early development could have meaningful neurological benefit. This is a hopeful signal for families of older children who may have wondered whether it was too late for targeted treatment.
Research into other gene activation platforms, including AAV-based gene therapy approaches, is also ongoing. The SCN2A field is advancing quickly, with growing investment from both academic institutions and the biotech sector. Families can support this momentum — and stay informed — by joining the SCN2A patient registry, which helps researchers understand the full scope of the LOF patient population and accelerates the path to clinical trials.
Research into SCN2A loss of function disorders has advanced meaningfully in recent years — but there is still a long road ahead to bring targeted therapies from laboratory findings to the families who need them most. Every family that registers, every dollar donated, and every story shared contributes to that journey.
Every family navigating an SCN2A loss of function diagnosis deserves answers, community, and hope. The work to find them depends on your support. Please consider making a donation to help fund the research and resources that move us all forward.
This content is provided for educational and informational purposes only and does not constitute medical advice. The information on this page is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.
4. Tamura S, et al. CRISPR Activation for SCN2A-Related Neurodevelopmental Disorders. Nature, 2025.
Vlad Magdalin
